Welcome to The HCPFive, your go-to roundup for the latest healthcare news and breakthroughs, curated specifically for busy healthcare professionals.

Each week, we highlight 5 key developments or headlines from healthcare that you need to know—whether it's a cutting-edge treatment, regulatory updates, or innovations shaping the future of medicine. This week's top stories include phase 3 data for obinutuzumab in primary membranous nephropathy as well as ixekizumab and tirzepatide in moderate-to-severe plaque psoriasis and obesity or overweight with ≥ 1 additional weight-related comorbid condition, new data supporting the cardiovascular benefits of AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted), findings from a second phase 3 trial evaluating COMP360 in treatment-resistant depression, and preclinical data for Thykamine™ in a human metabolic-associated steatohepatitis (MASH) model using PhysioMimix® Liver-on-a-Chip platform.

With The HCPFive, you'll get the essential takeaways to stay informed and ahead of the curve. Here’s your quick dive into the top stories for the week of February 15, 2026—let’s jump in!

MAJESTY: Obinutuzumab Achieves 2 Year Complete Remission in Primary Membranous Nephropathy

On February 16, 2026, Genentech, a member of the Roche Group, announced that the phase 3 MAJESTY study in adults with primary membranous nephropathy met its primary endpoint, showing statistically significant and clinically meaningful results with obinutuzumab (Gazyva).

In the study, significantly more people achieved complete remission at 2 years (104 weeks) with obinutuzumab versus tacrolimus, with no new safety signals identified. Genentech described plans to present the data at an upcoming medical meeting and share it with health authorities, including the US Food and Drug Administration.

Ixekizumab, Tirzepatide Effective Together for Psoriasis and Obesity or Overweight

On February 19, 2026, Eli Lilly and Company announced positive topline results from the landmark TOGETHER-PsO open-label phase 3b clinical trial evaluating the concomitant use of ixekizumab (Taltz) and tirzepatide (Zepbound) compared to ixekizumab alone in adults with moderate-to-severe plaque psoriasis and obesity or overweight with ≥ 1 additional weight-related comorbid condition.

Results showed that at 36 weeks, treatment with ixekizumab and tirzepatide met the primary and all key secondary endpoints, delivering superior skin clearance and weight loss versus ixekizumab monotherapy.

AREXVY Vaccine Reduces Hospitalization, Major Adverse Cardiovascular Events in RSV

On February 18, 2026, GSK announced new effectiveness data for AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) at RSVVW’26, the 9th Conference of the Respiratory Syncytial Virus Foundation (ReSViNET) in Rome, Italy.

This retrospective cohort study included >2.5 million patients, of whom 520,440 were vaccinated and matched in a 1:4 ratio to 2,081,760 patients who did not receive the vaccine. Results showed the vaccine was associated with 75.6% effectiveness against RSV-related hospitalization at a median follow-up period of 5.6 months post-vaccination. Additional exploratory endpoints indicated 63.1% vaccine effectiveness against major adverse cardiovascular events, including heart attack and stroke, during hospitalization among patients aged ≥60 years.

COMP360 Psilocybin Meets Primary Endpoint in Second Phase 3 Trial for TRD

On February 17, 2026, Compass Pathways announced that its investigational synthetic psilocybin formulation, COMP360, met the primary endpoint in the second pivotal phase 3 trial evaluating the therapy in adults with treatment-resistant depression.

In the COMP006 study, a pair of 25-mg doses administered 3 weeks apart produced a statistically significant reduction in depressive symptom severity at week 6 compared with a 1-mg dose control, reinforcing findings from the companion COMP005 trial and advancing the program toward regulatory submission.

Thykamine Shows Disease-Modifying Potential in MASH Using Liver-on-a-Chip Platform

On February 19, 2026, Devonian Health Group announced positive results from a follow-up preclinical study evaluating Thykamine™ in a human metabolic-associated steatohepatitis (MASH) model using PhysioMimix® Liver-on-a-Chip platform. The study was conducted by CN Bio Innovations, Cambridge, UK. The study demonstrates that Thykamine™ exerts dose-dependent effects on key pathological hallmarks of MASH, including fibrosis and inflammation, in a physiologically relevant human liver system, representing a notable translational bridge between Devonian’s previously disclosed efficacy in the mouse STAM® MASH model and a predictive human microphysiological model.

Articles

Phase 3 MAJESTY data showed obinutuzumab achieved higher 104-week complete remission rates than tacrolimus in primary membranous nephropathy, without new safety signals, supporting regulatory engagement. In TOGETHER-PsO, concomitant ixekizumab plus tirzepatide outperformed ixekizumab alone for skin clearance and weight loss in patients with plaque psoriasis and obesity/overweight with comorbidities. Real-world effectiveness data linked AREXVY to fewer RSV hospitalizations and exploratory reductions in in-hospital MACE. COMP360 synthetic psilocybin met a second pivotal TRD endpoint. Thykamine demonstrated dose-dependent anti-fibrotic and anti-inflammatory effects in a human Liver-on-a-Chip MASH model.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Hepatology

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

The HCPFive: Top News for Healthcare Providers from the Week of 02/15

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

Mark Creager, MD, FACC | Image Credit: Dartmouth Health

On February 19, 2026, the American Heart Association (AHA) and the American College of Cardiology (ACC) released the first clinical practice guidelines on the treatment of 

, detailing risk factors and recommending treatment and follow-up after diagnosis.

“There have been significant advances in the understanding of pulmonary embolism and treatments to effectively manage this condition,” Mark Creager, MD, FACC, professor of medicine at the Geisel School of Medicine at Dartmouth College, director emeritus of the Heart and Vascular Center at Dartmouth Health, and chair of the guideline writing committee, said in a statement. “This guideline is a road map to help clinicians navigate these advances for the safest and most effective approaches to care for people with this condition.”

The guidelines’ key takeaways, as listed by the investigator committee, are as follows:

Patients with acute PE who are asymptomatic can be safely discharged home. Early hospital discharge is also recommended for patients with acute PE who are symptomatic but have a low clinical severity score.

Symptomatic patients with acute PE and an elevated clinical severity score should be hospitalized to optimize treatment strategies. This includes those with elevated biomarkers and/or right ventricular dysfunction, cardiopulmonary failure with persistent hypotension, and incipient cardiopulmonary failure.

Low-molecular-weight heparin (LMWH) is recommended rather than unfractionated heparin (UFH) in patients with acute PE who need initial parental anticoagulant therapy.

Patients with acute PE eligible for oral anticoagulation should be given direct oral anticoagulants (DOACs) over vitamin K antagonists, unless contraindicated. These will prevent recurrent 

Patients with a first acute PE without a major reversible factor or with a persistent risk factor, continuing anticoagulation beyond the initial treatment phase of 3-6 months is recommended.

Patients with acute PE in AHA/ACC PE Category E1 should receive advanced therapies like systemic thrombolysis, catheter-based thrombolysis, mechanical thrombectomy, and surgical embolectomy. These treatments should also be considered for patients in AHA/ACC PE Category D1-2.

Patients who have had acute PE should regularly be asked about related symptoms and functional limitations at every clinic visit for ≥1 year to screen for causes of dyspnea and functional limitation like chronic thromboembolic pulmonary disease (CTEPD).

Additionally, the team highlighted factors that damage the veins or reduce blood flow, promoting the likelihood of clot formation and thereby increasing the risk of venous thromboembolism. These include prolonged immobility, pregnancy and postpartum within 6 weeks of delivery, use of oral contraceptives or estrogen treatment, obesity, smoking, atherosclerotic cardiovascular disease, and cancer, among others.

Patients with low or intermediate probability of acute PE based on symptom analysis should undergo a blood test for the measurement of D-dimer – elevated levels of this protein can signal the need for imaging to look for signs of a PE. The guidelines recommend computed tomography pulmonary angiography (CTPA) given its high accuracy and availability. For patients incapable of undergoing CTPA, the guidelines recommend screening via a lung ventilation/perfusion scan.

Additionally, the guidelines highlight the need for follow-up after treatment, including both physical and psychological aspects of care. The authors note depression, anxiety, and post-traumatic stress disorder as common in patients who have experienced acute PE. Physical activity and limiting long-distance travel are also encouraged to minimize the risk of further clotting.

“We anticipate that decisions guided by these recommendations will result in more rapid diagnosis and application of effective, evidence-based treatments, leading to better outcomes, such as decreased risk of death and disability, for people with acute pulmonary embolism,” Creager said.

American Heart Association. First AHA/ACC acute pulmonary embolism guideline: prompt diagnosis and treatment are key. 

. February 19, 2026. Accessed February 20, 2026. 

https://www.eurekalert.org/news-releases/1116906

Creager MA, Barnes GD, Giri J, et al. 2026 AHA/ACC/ACCP/ACEP/chest/SCAI/SHM/SIR/SVM/SVN guideline for the evaluation and management of Acute Pulmonary embolism in adults: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. Published online February 19, 2026. 

New AHA/ACC guidelines outline contemporary evaluation, risk stratification, treatment, and longitudinal care for acute pulmonary embolism. Disposition is guided by symptom burden and clinical severity, enabling safe outpatient management for low-risk patients while prioritizing hospitalization for higher-risk phenotypes with RV dysfunction, biomarker elevation, or evolving cardiopulmonary failure. Anticoagulation recommendations favor LMWH for initial parenteral therapy and DOACs for eligible patients, with extended therapy for unprovoked or persistent-risk PE. Diagnostic pathways emphasize D-dimer triage and CTPA, plus structured follow-up for CTEPD and mental health sequelae.

The new joint guidelines include a clinical classification system, major contributing factors, and recommendations for treatment and follow-up.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Venous Thromboembolism

The HCPLive venous thromboembolism page is a resource for medical news and expert insights on VTE. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for thrombotic disease, and more.

AHA and ACC Release First Guideline for Pulmonary Embolism Treatment

Ron Vender, MD, is a dermatologist in Hamilton, Ontario, and is the founder and director of Dermatrials Research Incorporated and Venderm Consulting Inc. He is also an associate clinical professor at McMaster University in the Department of Medicine, Division of Dermatology.

Interpreting 3-Year Data on Bimekizumab from BE RADIANT, With Ron Vender, MD

In the phase 3b BE RADIANT trial comparing bimekizumab with secukinumab in moderate to severe 

, investigators assessed not only traditional efficacy endpoints but also patient-reported outcomes (PROs) over 3 years. In discussing the results with 

, Ronald Vender, MD, suggests PROs are among the most meaningful measures for the assessment of chronic inflammatory diseases.

, one of the most striking observations was the rapid onset of symptom relief with bimekizumab. After only 1 dose, by Week 4, subjects reported absence of pruritus, skin pain, and scaling at higher rates than those treated with secukinumab therapy. In parallel, some subjects attained complete skin clearance (PASI 0) and a Dermatology Life Quality Index (DLQI) score of 0 or 1, suggesting a minimal impact of disease on quality of life. For Vender, that early combination of objective clearance and subjective symptom resolution points to the clinical importance of rapid psoriasis control.

At 1 year, symptom resolution remained more frequent with bimekizumab, and Vender highlighted that the durability of response through year 3 is particularly reassuring. He noted clinicians often worry about waning biologic efficacy over the course of time. However, sustained lack of itch, pain, and scaling, coupled with maintained low DLQI scores and continued PASI 0 responses, suggests durable benefit. Importantly, he cautioned that clear skin does not always automatically translate to a low DLQI, making the concurrent achievement of both endpoints clinically meaningful.

When asked about long-term interpretation, Vender described the 3-year efficacy data as providing confidence in continued skin clearance and sustained quality-of-life improvements. He framed these results as supportive of ongoing utilization in appropriate patients, allowing clinicians to reassure those for whom the benefits can persist.

Finally, regarding a question on treatment sequencing, Vender described patients who shifted from secukinumab to bimekizumab as having experienced further improvements in symptom control and clearance. While acknowledging secukinumab remains an effective medication, he suggested the switching data suggest additional gains in PROs may be attainable with dual IL-17A/F inhibition in select individuals.

The quotes included in this summary were edited for clarity.

Vender reported support from AbbVie, Alumis, Amgen, Arcutis, Bausch, Bristol Myers Squibb, Celltrion, JAMP, Janssen, Leo, Lilly, Meiji, Novartis, Organon, Orka, Sandoz, Sun, Takeda, and UCB.

Augustin M, Feldman SR, Warren RB, et al. Three-Year Patient-Reported Outcomes From Bimekizumab for Plaque Psoriasis: The BE RADIANT Randomized Clinical Trial With Open-Label Extension. JAMA Dermatol. Published online February 18, 2026. 

Smith T. BE RADIANT Trial: Bimekizumab Effective for Psoriasis After 3 Years of Use. HCPLive. February 19, 2026. Accessed February 20, 2026. 

https://www.hcplive.com/view/be-radiant-trial-bimekizumab-effective-psoriasis-after-3-years-use

Videos

In this segment of his interview, Vender highlighted his own views on the significance of BE RADIANT trial findings on bimekizumab for psoriasis.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

COMP360 Psilocybin Shows Rapid, Durable Effect in TRD, With Steve Levine, MD

Following positive topline results from the phase 3 COMP006 trial, 

 spoke with Steve Levine, MD, chief patient officer of Compass Pathways, to contextualize the clinical relevance of COMP360 (synthetic psilocybin) for treatment-resistant 

“One of the most striking things about the data we've just presented from our 05 and 06 studies is the rapidity of onset,” Levine told 

. “In both cases, we were able to detect a clinically and statistically significant difference in MADRS reduction as of day 2, which is the first day after administration of COMP360. That is a rapidity of effect that we've never seen before.”

Levine said the rapid onset may reflect acute, network-level effects mediated through 5-HT2A receptor agonism. He noted that this mechanism appears distinct from those underlying currently available treatments for TRD.

In COMP006, two 25-mg doses of COMP360 administered 3 weeks apart demonstrated a –3.8-point least squares mean difference in Montgomery-Åsberg Depression Rating Scale (MADRS) score at week 6 compared with a 1-mg control (

 <.001). According to Levine, a 3-point MADRS difference is generally considered clinically meaningful in TRD, placing the 3.8-point separation above the accepted threshold for relevance.

He noted that the magnitude of effect is comparable to that observed in pivotal trials of esketamine (Spravato), currently the only FDA-approved medication specifically indicated for TRD. However, whereas esketamine’s approximately 4-point treatment difference was achieved after multiple administrations over 4 weeks, COMP360 demonstrated a similar effect size 6 weeks after a single administration in COMP005 and after 2 administrations in COMP006.

In Part B of COMP005, participants who achieved ≥ 25% reduction in MADRS at week 6 and received a second treatment demonstrated sustained benefit through week 26. Among those with an initial clinically meaningful response who underwent re-treatment, approximately 40% achieved remission. These findings suggest that 1 or 2 administrations may support symptom improvement lasting up to 6 months in responders.

Furthermore, in COMP005, 25% of participants receiving 25 mg achieved a ≥ 25% MADRS reduction versus placebo. In COMP006, 39% reached this threshold after a second administration.

“This is a level of improvement that is very likely to translate into really meaningful benefit for patients, particularly those who have treatment-resistant depression,” Levine said. “Even modest decreases in symptoms can have an outsized impact on the course of their care and the quality of their life.”

A relevant disclosure for Levine includes Janssen Pharmaceuticals, Inc.

Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression. Compass Pathways. Published on February 17, 2026. Accessed on February 19, 2026. 

https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Successfully-Achieves-Primary-Endpoint-in-Second-Phase-3-Trial-Evaluating-COMP360-Psilocybin-for-Treatment-Resistant-Depression/default.aspx

Derman C. COMP360 Psilocybin Meets Primary Endpoint in Second Phase 3 Trial for TRD. HCPLive. Published on February 19, 2026. Accessed on February 20, 2026. 

https://www.hcplive.com/view/comp360-psilocybin-meets-primary-endpoint-second-phase-3-trial-trd

Levine breaks down Compass Pathways’ phase 3 data on COMP360, highlighting next-day onset and sustained symptom improvement through 26 weeks.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

Raja Atreya, MD, is head of the IBD Center at University Hospital

Sustained Remission in Hard-to-Treat Crohn’s: Insights From SEQUENCE

New long-term data from the SEQUENCE program, presented at the 2026 Congress of the European Crohn’s and Colitis Organisation (ECCO), continue to reinforce the clinical impact of risankizumab (Skyrizi) in moderate-to-severe Crohn’s disease, particularly among patients with prior anti-TNF failure.

In discussing the findings, Raja Atreya, MD, head of the IBD Center at University Hospital

of Erlangen, characterized SEQUENCE as a “landmark” trial and emphasized that its design and durability data are directly shaping real-world decision-making.

“This is a head-to-head trial addressing an unmet need that we have in the treatment of our patients with exposure to anti-TNF therapy. This is a common clinical problem that we have,” Atreya explained. “I'm glad that I'm practicing in these times where we have a lot of therapeutic options. In the setting of previous anti TNF failure, where we already know these are hard to treat patients, because failure to anti TNF is like a surrogate marker for severe disease, hard to treat disease, refractory disease. So having these biological options is very nice, but when choosing the second advanced therapy, you have to make the right choice.”

He stressed that the head-to-head comparison of risankizumab and ustekinumab provided critically needed direct comparative data in this hard-to-treat population, something that has historically been lacking in Crohn’s disease.

The analysis included 224 patients who completed part 1 of the SEQUENCE study (week 48) and could receive risankizumab 360mg subcutaneously (SC) every 8 weeks in part 2, the open-label maintenance period of the SEQUENCE trial, starting at week 52.

Results showed patients with moderate-to-severe Crohn’s disease and prior anti-TNF failure, a population generally considered to have more refractory disease, demonstrated durable clinical remission, endoscopic response, endoscopic remission, and mucosal healing through 148 weeks of risankizumab treatment in the SEQUENCE study.

Of note, most patients who achieved clinical remission at week 8 maintained clinical remission throughout later time points, and clinical remission at week 148 was achieved by the majority (98.5% by CDAI; 88.1% by SF/APS) of week 8 clinical remitters.

Investigators additionally observed durability of clinical remission throughout later time points in patients who achieved clinical remission at week 48.

Of patients who achieved endoscopic response, endoscopic remission, or mucosal healing at week 24, 84.7%, 78.2%, and 67.3% of patients, respectively, maintained the corresponding endpoint at week 148. Similar results at week 148 were observed for patients who achieved these endoscopic endpoints at week 48.

Atreya further emphasized that early response appears to be the strongest predictor of long-term success. While molecular predictors remain elusive, he noted that patients who achieve early clinical and endoscopic remission are most likely to sustain benefit over time.

“With the amazing treatment results that we see in the SEQUENCE study and the sustained effectiveness seen in the open label extension studies, this is really something that helps us to position risankizumab high up in my personal therapeutic algorithm,” Atreya said.

Editors’ Note: Atreya reports relevant disclosures with AbbVie, Abivax, AlfaSigma, Astra-Zeneca, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celltrion Healthcare, Gilead, GlaxoSmithKline, Johnson & Johnson, Lilly, Merck Sharpe & Dohme, Pfizer, Roche Pharma, Takeda Pharma, and others.

R Atreya, J Lindsay, M Ferrante, B Siegmund, Q Cao, S Van Haaren, J Crowley, T Anschutz, A Garrison, X Huang, M C Dubinsky, DOP004 Durable Efficacy of Risankizumab Through Week 148 in Patients With Moderate-to-Severe Crohn’s Disease: A Post Hoc Analysis of Part 2 of the SEQUENCE Study, 

, Volume 20, Issue Supplement_1, January 2026, jjaf231.041, 

https://doi.org/10.1093/ecco-jcc/jjaf231.041

Brooks A. Marla Dubinsky, MD: Clinical Outcomes with Risankizumab Versus Ustekinumab in SEQUENCE. HCPLive. February 24, 2024. Accessed February 20, 2026. 

https://www.hcplive.com/view/marla-dubinsky-md-clinical-outcomes-risankizumab-ustekinumab-sequence

SEQUENCE trial data highlight sustained 3-year clinical and endoscopic remission with risankizumab in anti-TNF–exposed Crohn’s patients.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Inflammatory Bowel Disease

On the HCPLive inflammatory bowel disease page, resources on the topics of medical news and expert insight into IBD can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBD and more.

How Head-to-Head SEQUENCE Data Shape Crohn’s Disease Treatment Decisions, With Raja Atreya, MD

Victoria Johnson joined the MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and now HCPLive. You can reach her at vjohnson@mjhlifesciences.com

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Frontline COPD Care in the Biologic Era: Practical Insights From APPs

Diana Isaacs, PharmD, is an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic.

1 year into real-world use, 4 clinicians discuss how semaglutide is transforming the endocrinology, nephrology, and cardiology landscape.


Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Chronic Kidney Disease

Type 2 Diabetes

Strategic Alliance Partnership

1 Year After CKD Approval, Semaglutide Transforms Diabetes, Kidney, and Heart Care

This interview with Vender highlights recent findings on patient-reported outcomes (PROs) in patients in the BE RADIANT trial with psoriasis.

3-Year Patient-Reported Psoriasis Outcomes for Bimekizumab, With Ron Vender, MD

Panaccione recaps interim PROFUNDUS data showing real-world efficacy and safety of upadacitinib (Rinvoq) for ulcerative colitis.

PROFUNDUS: Real-World Outcomes With Upadacitinib in Ulcerative Colitis, With Remo Panaccione, MD

Chelsie Derman is an associate editor for 

who covers psychiatry, sleep medicine, geriatrics, migraine, and allergy. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

A phase 2a randomized, placebo-controlled study shows –7.35 MADRS difference at 2 weeks with SPL026 compared with placebo. However, the study is not advancing.


Intravenous DMT (SPL026) Demonstrates Significant MDD Reduction in Phase 2a Trial

Andres Hurtado-Lorenzo, PhD, is VP of IBD Ventures and Translational Research at the Crohn’s & Colitis Foundation.

Hurtado-Lorenzo explains the growing interest in meal timing as a potential lifestyle intervention for Crohn’s and recent trial data supporting its utility in this patient population.

Meal Timing and Crohn’s Disease: Clinical Implications of Intermittent Fasting, With Andres Hurtado-Lorenzo, PhD

Janani Rangaswami, MD, FAHA, a nephrologist with expertise in cardiovascular- kidney medicine; Professor of Medicine, George Washington University, Washington DC; Co-chair, Scientific Advisory Group of the AHA's presidential advisory on CKM Health.

CKM syndrome affects nearly 90% of US adults, highlighting the need to manage cardiovascular, kidney, and metabolic risk together.


Why Cardiovascular, Kidney, Metabolic Risk Must Be Managed Together, With Janani Rangaswami, MD, FAHA

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

In the phase 3b BE RADIANT trial and its open-label extension, bimekizumab treatment led to durable improvements in patient-reported outcomes over 3 years.

BE RADIANT Trial: Bimekizumab Effective for Psoriasis After 3 Years of Use

Justin Ezekowitz, MD, is a professor of medicine at University of Alberta and a cardiologist at the University of Alberta Hospital and Mazankowski Alberta Heart Institute

Ezekowitz discusses his recent secondary analysis of the SODIUM-HF trial, highlighting the MAGGIC analysis data that implied a very limited benefit.

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Sodium Restrictions May Only Benefit Patients at Low Risk of HF, With Justin Ezekowitz, MD

Targeting CD28 and CD154 pathways, dual blockade with belatacept and dazodalibep offers potential to improve adherence in kidney transplant recipients.



Latest News

The HCPFive: Top News for Healthcare Providers from the Week of 02/15

AHA and ACC Release First Guideline for Pulmonary Embolism Treatment

Interpreting 3-Year Data on Bimekizumab from BE RADIANT, With Ron Vender, MD

COMP360 Psilocybin Shows Rapid, Durable Effect in TRD, With Steve Levine, MD

How Head-to-Head SEQUENCE Data Shape Crohn’s Disease Treatment Decisions, With Raja Atreya, MD